Insight on submission of USFDA sBLA of Tremfya (guselkumab) for the treatment of adult patients with active psoriatic arthritis (PsA)
Posted on18 Sep 2019
TagsJanssen, Janssen Biotech, Janssen Pharma, MorphoSys AG, sBLA, supplemental Biologics License Application, Tremfya
Comments0
MorphoSys AG, a clinical-stage biopharmaceutical company, announced that its licensee Janssen Research & Development, submitted a supplemental Biologics License Application (sBLA) to... Read More
US FDA accepts Roche’s sBLA for Tecentriq in combo with Abraxane and carboplatin to treat metastatic NSCLC
Roche announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Tecentriq (atezolizumab)... Read More